vs
Side-by-side financial comparison of Labcorp (LH) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $3.5B, roughly 1.0× Labcorp). On growth, Labcorp posted the faster year-over-year revenue change (5.6% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $490.3M). Over the past eight quarters, Labcorp's revenue compounded faster (5.2% CAGR vs 0.5%).
Labcorp is a leading global life sciences and diagnostic testing firm that offers comprehensive clinical laboratory services, drug development support, and medical testing solutions for healthcare providers, pharmaceutical companies, and individual patients. It uses advanced scientific expertise and innovative technologies to deliver accurate, actionable health insights that support clinical decisions, accelerate new treatment development, and improve patient health outcomes globally.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
LH vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $3.7B |
| Net Profit | $164.7M | — |
| Gross Margin | 28.2% | 31.1% |
| Operating Margin | 7.6% | -5.2% |
| Net Margin | 4.7% | — |
| Revenue YoY | 5.6% | 5.0% |
| Net Profit YoY | 14.9% | — |
| EPS (diluted) | $1.98 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5B | $3.7B | ||
| Q3 25 | $3.6B | $3.7B | ||
| Q2 25 | $3.5B | $3.6B | ||
| Q1 25 | $3.3B | $3.2B | ||
| Q4 24 | $3.3B | $3.5B | ||
| Q3 24 | $3.3B | $3.7B | ||
| Q2 24 | $3.2B | $3.8B | ||
| Q1 24 | $3.2B | $3.7B |
| Q4 25 | $164.7M | — | ||
| Q3 25 | $261.1M | — | ||
| Q2 25 | $237.9M | — | ||
| Q1 25 | $212.8M | — | ||
| Q4 24 | $143.4M | — | ||
| Q3 24 | $169.3M | — | ||
| Q2 24 | $205.3M | — | ||
| Q1 24 | $228.0M | — |
| Q4 25 | 28.2% | 31.1% | ||
| Q3 25 | 28.8% | 36.6% | ||
| Q2 25 | 29.7% | 37.3% | ||
| Q1 25 | 28.3% | 35.8% | ||
| Q4 24 | 26.9% | 34.6% | ||
| Q3 24 | 27.6% | 39.0% | ||
| Q2 24 | 28.8% | 38.2% | ||
| Q1 24 | 28.2% | 41.2% |
| Q4 25 | 7.6% | -5.2% | ||
| Q3 25 | 11.1% | 4.8% | ||
| Q2 25 | 11.2% | 6.5% | ||
| Q1 25 | 9.7% | -88.9% | ||
| Q4 24 | 6.5% | -5.1% | ||
| Q3 24 | 7.7% | 6.0% | ||
| Q2 24 | 9.2% | -6.3% | ||
| Q1 24 | 10.1% | 5.6% |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | 6.7% | — | ||
| Q1 25 | 6.4% | — | ||
| Q4 24 | 4.3% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 6.4% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | $1.98 | $-0.34 | ||
| Q3 25 | $3.12 | $-0.11 | ||
| Q2 25 | $2.84 | $0.00 | ||
| Q1 25 | $2.52 | $-2.55 | ||
| Q4 24 | $1.72 | $-0.43 | ||
| Q3 24 | $2.00 | $0.08 | ||
| Q2 24 | $2.43 | $-0.27 | ||
| Q1 24 | $2.69 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $532.3M | $1.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.6B | $14.7B |
| Total Assets | $18.4B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $532.3M | $1.3B | ||
| Q3 25 | $598.1M | $975.3M | ||
| Q2 25 | $647.3M | $566.4M | ||
| Q1 25 | $369.4M | $755.0M | ||
| Q4 24 | $1.5B | $734.8M | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $265.1M | $917.2M | ||
| Q1 24 | $99.3M | $1.0B |
| Q4 25 | $8.6B | $14.7B | ||
| Q3 25 | $8.7B | $15.2B | ||
| Q2 25 | $8.5B | $15.6B | ||
| Q1 25 | $8.3B | $15.7B | ||
| Q4 24 | $8.1B | $18.6B | ||
| Q3 24 | $8.2B | $19.8B | ||
| Q2 24 | $8.0B | $19.5B | ||
| Q1 24 | $8.0B | $20.0B |
| Q4 25 | $18.4B | $37.2B | ||
| Q3 25 | $18.3B | $37.9B | ||
| Q2 25 | $18.1B | $38.4B | ||
| Q1 25 | $17.6B | $38.5B | ||
| Q4 24 | $18.4B | $41.5B | ||
| Q3 24 | $18.6B | $44.8B | ||
| Q2 24 | $16.7B | $45.3B | ||
| Q1 24 | $16.5B | $47.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $614.2M | $815.8M |
| Free Cash FlowOCF − Capex | $490.3M | $619.3M |
| FCF MarginFCF / Revenue | 13.9% | 16.8% |
| Capex IntensityCapex / Revenue | 3.5% | 5.3% |
| Cash ConversionOCF / Net Profit | 3.73× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $614.2M | $815.8M | ||
| Q3 25 | $387.2M | $744.9M | ||
| Q2 25 | $620.6M | $219.7M | ||
| Q1 25 | $18.5M | $535.5M | ||
| Q4 24 | $777.2M | $482.7M | ||
| Q3 24 | $277.3M | $826.5M | ||
| Q2 24 | $561.1M | $379.1M | ||
| Q1 24 | $-29.8M | $614.6M |
| Q4 25 | $490.3M | $619.3M | ||
| Q3 25 | $280.5M | $658.1M | ||
| Q2 25 | $542.7M | $166.8M | ||
| Q1 25 | $-107.5M | $492.9M | ||
| Q4 24 | $665.1M | $342.3M | ||
| Q3 24 | $161.5M | $749.5M | ||
| Q2 24 | $432.9M | $320.3M | ||
| Q1 24 | $-163.6M | $564.8M |
| Q4 25 | 13.9% | 16.8% | ||
| Q3 25 | 7.9% | 17.6% | ||
| Q2 25 | 15.4% | 4.7% | ||
| Q1 25 | -3.2% | 15.2% | ||
| Q4 24 | 20.0% | 9.7% | ||
| Q3 24 | 4.9% | 20.1% | ||
| Q2 24 | 13.4% | 8.5% | ||
| Q1 24 | -5.2% | 15.5% |
| Q4 25 | 3.5% | 5.3% | ||
| Q3 25 | 3.0% | 2.3% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 3.8% | 1.3% | ||
| Q4 24 | 3.4% | 4.0% | ||
| Q3 24 | 3.5% | 2.1% | ||
| Q2 24 | 4.0% | 1.6% | ||
| Q1 24 | 4.2% | 1.4% |
| Q4 25 | 3.73× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 2.61× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 5.42× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 2.73× | — | ||
| Q1 24 | -0.13× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
